WO2001051633A3 - Compositions et methodes destinees au traitement et au diagnostique du cancer de la prostate - Google Patents

Compositions et methodes destinees au traitement et au diagnostique du cancer de la prostate Download PDF

Info

Publication number
WO2001051633A3
WO2001051633A3 PCT/US2001/001574 US0101574W WO0151633A3 WO 2001051633 A3 WO2001051633 A3 WO 2001051633A3 US 0101574 W US0101574 W US 0101574W WO 0151633 A3 WO0151633 A3 WO 0151633A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
diagnosis
prostate cancer
therapy
methods
Prior art date
Application number
PCT/US2001/001574
Other languages
English (en)
Other versions
WO2001051633A2 (fr
WO2001051633A9 (fr
Inventor
Jiangchun Xu
Davin C Dillon
Jennifer L Mitcham
Susan L Harlocker
Yuqiu Jiang
Steven G Reed
Michael D Kalos
Gary Richard Fanger
Craig H Day
Marc W Retter
John A Stolk
Yasir A W Skeiky
Aijun Wang
Madeleine Joy Meagher
Original Assignee
Corixa Corp
Jiangchun Xu
Davin C Dillon
Jennifer L Mitcham
Susan L Harlocker
Yuqiu Jiang
Steven G Reed
Michael D Kalos
Gary Richard Fanger
Craig H Day
Marc W Retter
John A Stolk
Yasir A W Skeiky
Aijun Wang
Madeleine Joy Meagher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP01906582A priority Critical patent/EP1261708A2/fr
Priority to MXPA02006934A priority patent/MXPA02006934A/es
Priority to AU34474/01A priority patent/AU3447401A/en
Priority to BR0107643-4A priority patent/BR0107643A/pt
Priority to CA002397741A priority patent/CA2397741A1/fr
Priority to IL15073201A priority patent/IL150732A0/xx
Application filed by Corixa Corp, Jiangchun Xu, Davin C Dillon, Jennifer L Mitcham, Susan L Harlocker, Yuqiu Jiang, Steven G Reed, Michael D Kalos, Gary Richard Fanger, Craig H Day, Marc W Retter, John A Stolk, Yasir A W Skeiky, Aijun Wang, Madeleine Joy Meagher filed Critical Corixa Corp
Priority to HU0203968A priority patent/HUP0203968A3/hu
Priority to JP2001551207A priority patent/JP2003528591A/ja
Publication of WO2001051633A2 publication Critical patent/WO2001051633A2/fr
Publication of WO2001051633A3 publication Critical patent/WO2001051633A3/fr
Priority to NO20023402A priority patent/NO20023402L/no
Publication of WO2001051633A9 publication Critical patent/WO2001051633A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464494—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des compositions et des méthodes destinées au traitement et au diagnostique de cancer, plus précisément le cancer de la prostate. Ces compositions comprennent un ou plusieurs polypeptides spécifiques de la prostate, des portions immunogéniques de ces polypeptides, des polynucléotides codant pour ces polypeptides, une cellule présentant un antigène qui exprime ces polypeptides, et des cellules T qui sont spécifiques des cellules exprimant ces polypetides. Les compositions selon l'invention conviennent, par exemple, pour le diagnostique, la prévention et/ou le traitement de maladies, notamment le cancer de la prostate.
PCT/US2001/001574 2000-01-14 2001-01-16 Compositions et methodes destinees au traitement et au diagnostique du cancer de la prostate WO2001051633A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MXPA02006934A MXPA02006934A (es) 2000-01-14 2001-01-16 Composiciones y metodos para la terapia y diagnostico de cancer de prostata.
AU34474/01A AU3447401A (en) 2000-01-14 2001-01-16 Compositions and methods for the therapy and diagnosis of prostate cancer
BR0107643-4A BR0107643A (pt) 2000-01-14 2001-01-16 Composições e processos para a terapia e diagnóstico de c ncer de próstata
CA002397741A CA2397741A1 (fr) 2000-01-14 2001-01-16 Compositions et methodes destinees au traitement et au diagnostique du cancer de la prostate
IL15073201A IL150732A0 (en) 2000-01-14 2001-01-16 Prostate specific polypeptides, polynucleotides that encode said polypeptides and pharmaceutical compositions containing the same
EP01906582A EP1261708A2 (fr) 2000-01-14 2001-01-16 Compositions et methodes destinees au traitement et au diagnostique du cancer de la prostate
HU0203968A HUP0203968A3 (en) 2000-01-14 2001-01-16 Compositions and methods for the therapy and diagnosis of prostate cancer
JP2001551207A JP2003528591A (ja) 2000-01-14 2001-01-16 前立腺癌の治療及び診断のための組成物及び方法
NO20023402A NO20023402L (no) 2000-01-14 2002-07-15 Blandinger og fremgangsmåter for behandling og diagnose av prostatakreft

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48367200A 2000-01-14 2000-01-14
US09/483,672 2000-01-14

Publications (3)

Publication Number Publication Date
WO2001051633A2 WO2001051633A2 (fr) 2001-07-19
WO2001051633A3 true WO2001051633A3 (fr) 2002-06-20
WO2001051633A9 WO2001051633A9 (fr) 2002-10-31

Family

ID=23921037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/001574 WO2001051633A2 (fr) 2000-01-14 2001-01-16 Compositions et methodes destinees au traitement et au diagnostique du cancer de la prostate

Country Status (16)

Country Link
EP (1) EP1261708A2 (fr)
JP (1) JP2003528591A (fr)
KR (1) KR20030016217A (fr)
CN (1) CN1436234A (fr)
AU (1) AU3447401A (fr)
BR (1) BR0107643A (fr)
CA (1) CA2397741A1 (fr)
CZ (1) CZ20022756A3 (fr)
HU (1) HUP0203968A3 (fr)
IL (1) IL150732A0 (fr)
MX (1) MXPA02006934A (fr)
NO (1) NO20023402L (fr)
PL (1) PL356908A1 (fr)
RU (1) RU2002121771A (fr)
WO (1) WO2001051633A2 (fr)
ZA (1) ZA200206400B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096907B2 (en) 2004-12-24 2015-08-04 Stichting Katholieke Universiteit, The University Medical Centre Nijmegen Prostate cancer prognostic compositions and kits

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125536A1 (en) * 1996-01-11 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6828431B1 (en) 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6613872B1 (en) 1997-02-25 2003-09-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
ES2402947T3 (es) 1997-04-10 2013-05-10 Stichting Katholieke Universiteit University Medical Centre Nijmegen PCA3, genes PCA3 y métodos de uso
US6861215B1 (en) 1998-05-21 2005-03-01 Diadexus, Inc. Method of diagnosing, monitoring, and staging prostate cancer
DK1086223T3 (da) 1998-06-01 2009-11-30 Agensys Inc Nye serpentintransmembranantigener udtrykt i humane cancerformer og anvendelser deraf
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US7022497B1 (en) 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
ATE321857T1 (de) 1999-09-29 2006-04-15 Diagnocure Inc Pca3 mrna in gutartigen und bösartigen prostatageweben
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
CA2386854A1 (fr) * 1999-10-07 2001-04-12 Corixa Corporation Utilisation d'une sequence codante de mycobacterium tuberculosis pour favoriser une expression stable et de fort rendement de proteines heterologues
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
AU2001249549A1 (en) * 2000-03-27 2001-10-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2413959C (fr) 2000-06-20 2015-07-07 Corixa Corporation Proteines de fusion du mycobacterium tuberculosis
WO2002006537A2 (fr) * 2000-07-13 2002-01-24 Curagen Corporation Methodes permettant d'identifier des facteurs de protection renaux
CA2417671A1 (fr) 2000-07-28 2002-02-07 Ulrich Wissenbach Marqueurs trp8, trp9 et trp10 associes au cancer
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2443123A1 (fr) 2001-04-10 2002-10-24 Agensys, Inc. Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
EP1988097A1 (fr) * 2001-05-09 2008-11-05 Corixa Corporation Compositions et procédés pour le traitement et le diagnostic du cancer de la prostate
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
EP2000545B1 (fr) 2001-06-20 2011-08-31 Genentech, Inc. Compositions et procédés pour le traitement et le diagnostic d'une tumeur pulmonaire
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP2005505271A (ja) * 2001-09-06 2005-02-24 アジェンシス， インコーポレイテッド 癌の処置および検出において有用なｓｔｅａｐ−１と名称が与えられる核酸および対応するタンパク質
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
AU2003210663A1 (en) 2002-01-25 2003-09-02 The Regents Of The University Of California Methods of modulating cold sensory perception
DE10215321A1 (de) * 2002-04-02 2003-10-23 Metagen Pharmaceuticals Gmbh Trp-p8 Splice Varianten und regulatorische RNA
DE60313163T2 (de) * 2002-06-11 2008-01-03 Glaxosmithkline Biologicals S.A. Immunogene zusammensetzungen
DE10234901A1 (de) * 2002-07-26 2004-02-12 Metagen Pharmaceuticals Gmbh Verwendung von am Mrp4 bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen
WO2004016733A2 (fr) 2002-08-16 2004-02-26 Agensys, Inc. Acides nucleiques et proteines correspondantes connues sous 251p5g2 que l'on utilise dans le traitement et la detection de cancers
AU2004209578A1 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
BRPI0418766B8 (pt) 2004-04-22 2021-05-25 Agensys Inc anticorpo ou seu fragmento, vetor, composição farmacêutica, ensaio e método para detectar a presença de proteína steap-1, bem como método para distribuir um agente citotóxico ou um agente de diagnóstico
KR20080016955A (ko) * 2005-06-14 2008-02-22 디나벡크 가부시키가이샤 항체의 제작방법
ES2636089T3 (es) 2006-10-27 2017-10-05 Genentech, Inc. Anticuerpos e inmunoconjugados y usos para los mismos
KR102247979B1 (ko) * 2012-05-25 2021-05-04 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
CN104357451B (zh) * 2014-12-02 2016-09-21 广州市番禺区中心医院 针对dd3基因的小干扰rna及其表达载体构建与应用
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520566D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CN116970061A (zh) * 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
CA3055132A1 (fr) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Anticorps se liant a steap-1
CN110988348B (zh) * 2019-11-06 2022-07-05 北京九强生物技术股份有限公司 游离前列腺特异性抗原检测试剂盒及其制备方法
CN114250238B (zh) * 2021-11-26 2023-08-25 北京航空航天大学 基因编码的神经元发育调控多肽及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033909A2 (fr) * 1996-03-15 1997-09-18 Corixa Corporation Composes et methodes d'immunotherapie et d'immunodiagnostic pour le cancer de la prostate
WO1998037093A2 (fr) * 1997-02-25 1998-08-27 Corixa Corporation Composes permettant l'immunotherapie du cancer de la prostate et procedes concernant leur utilisation
WO1998037418A2 (fr) * 1997-02-25 1998-08-27 Corixa Corporation Composes servant au diagnostic immunologique de cancer de la prostate et leurs procedes d'utilisation
WO2000004149A2 (fr) * 1998-07-14 2000-01-27 Corixa Corporation Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2001025272A2 (fr) * 1999-10-04 2001-04-12 Corixa Corporation Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2001034802A2 (fr) * 1999-11-12 2001-05-17 Corixa Corporation Compositions et methodes de traitement et de diagnostic du cancer de la prostate

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033909A2 (fr) * 1996-03-15 1997-09-18 Corixa Corporation Composes et methodes d'immunotherapie et d'immunodiagnostic pour le cancer de la prostate
WO1998037093A2 (fr) * 1997-02-25 1998-08-27 Corixa Corporation Composes permettant l'immunotherapie du cancer de la prostate et procedes concernant leur utilisation
WO1998037418A2 (fr) * 1997-02-25 1998-08-27 Corixa Corporation Composes servant au diagnostic immunologique de cancer de la prostate et leurs procedes d'utilisation
WO2000004149A2 (fr) * 1998-07-14 2000-01-27 Corixa Corporation Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2001025272A2 (fr) * 1999-10-04 2001-04-12 Corixa Corporation Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2001034802A2 (fr) * 1999-11-12 2001-05-17 Corixa Corporation Compositions et methodes de traitement et de diagnostic du cancer de la prostate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SJOGREN H O: "Therapeutic immunization against cancer antigens using genetically engineered cells", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 3, no. 3, 1 October 1997 (1997-10-01), pages 161 - 172, XP004097000, ISSN: 1380-2933 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096907B2 (en) 2004-12-24 2015-08-04 Stichting Katholieke Universiteit, The University Medical Centre Nijmegen Prostate cancer prognostic compositions and kits

Also Published As

Publication number Publication date
HUP0203968A2 (hu) 2003-03-28
EP1261708A2 (fr) 2002-12-04
CA2397741A1 (fr) 2001-07-19
RU2002121771A (ru) 2004-03-10
CN1436234A (zh) 2003-08-13
IL150732A0 (en) 2003-02-12
MXPA02006934A (es) 2003-01-28
AU3447401A (en) 2001-07-24
BR0107643A (pt) 2003-06-10
HUP0203968A3 (en) 2004-09-28
CZ20022756A3 (cs) 2003-02-12
PL356908A1 (en) 2004-07-12
NO20023402L (no) 2002-08-29
JP2003528591A (ja) 2003-09-30
KR20030016217A (ko) 2003-02-26
WO2001051633A2 (fr) 2001-07-19
WO2001051633A9 (fr) 2002-10-31
ZA200206400B (en) 2004-01-21
NO20023402D0 (no) 2002-07-15

Similar Documents

Publication Publication Date Title
WO2001051633A3 (fr) Compositions et methodes destinees au traitement et au diagnostique du cancer de la prostate
WO2001073032A3 (fr) Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2002089747A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer de la prostate
WO2004052276A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer de la prostate
WO2001092581A8 (fr) Compositions et methodes permettant le traitement et le diagnostic du cancer de l'ovaire
WO2002060317A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du pancreas
WO2001072295A3 (fr) Compositions et methodes pouvant traiter ou diagnostiquer le cancer du poumon
WO2002074156A3 (fr) Compositions et procedes de therapie et de diagnostic du cancer du colon
WO2002014503A3 (fr) Compositions et methodes de traitement et de diagnostic de cancers associes a her-2/neu
WO2002004514A3 (fr) Compositions et procedes pour le traitement et le diagnostic du cancer du poumon
WO2002074237A3 (fr) Compositions et procedes de therapie et de diagnostic du cancer du rein
WO2002092001A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer du poumon
WO2002012328A8 (fr) Compositions et methodes utilisees dans la therapie et le diagnostic du cancer du colon
WO2002016413A3 (fr) Vaccins
WO2002058534A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du colon
WO2003037267A8 (fr) Compositions et methodes de traitement et de diagnostic du cancer des poumons
WO2002078516A3 (fr) Compositions et methodes de traitement et de diagnostic de cancers
WO2001077168A3 (fr) Compositions et procedes permettant de traiter et de diagnostiquer le cancer du poumon
WO2002012280A3 (fr) Compositions et procedes pour le diagnostic et le traitement du cancer du colon
WO2002039885A3 (fr) Compositions et methodes destinees a la therapie et au diagnostic du cancer de l'ovaire
WO2003013431A3 (fr) Compositions et techniques de therapie et de diagnostic du cancer du sein
WO2001090152A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du sein
WO2002000174A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du poumon
WO2005051990A3 (fr) Compositions et procedes pour le traitement et le diagnostic du cancer du sein
WO2003086175A3 (fr) Compositions et procedes destines au traitement et au diagnostic du cancer du poumon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 150732

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2001 551207

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020027009144

Country of ref document: KR

Ref document number: 2397741

Country of ref document: CA

Ref document number: PA/a/2002/006934

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 520395

Country of ref document: NZ

Ref document number: 34474/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/01042/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002/06400

Country of ref document: ZA

Ref document number: 200206400

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PV2002-2756

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2002 2002121771

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001906582

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018065260

Country of ref document: CN

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/12-12/12, DRAWINGS, REPLACED BY NEW PAGES 1/10-10/10; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 2001906582

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2002-2756

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020027009144

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2002-2756

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001906582

Country of ref document: EP